4-(1H-imidazole-1-carbonyl)benzoic acid methyl ester | 112497-47-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(1H-imidazole-1-carbonyl)benzoic acid methyl ester
• 英文别名: methyl 4-(1H-imidazole-1-carbonyl)benzoate；methyl 4-(imidazole-1-carbonyl)benzoate
• CAS: 112497-47-9
• 化学式: C₁₂H₁₀N₂O₃
• 分子量: 230.223
• InChiKey: NETPLBLJSFFJOY-UHFFFAOYSA-N

物化性质

• 沸点：
  425.5±47.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  61.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(1H-imidazole-1-carbonyl)benzoic acid methyl ester 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 35.0h， 生成
  参考文献：
  名称：

  JP5972748

  摘要：

  公开号：
• 作为产物：
  描述：

  对苯二甲酸单甲酯 、 N,N'-羰基二咪唑 以 四氢呋喃 为溶剂， 生成 4-(1H-imidazole-1-carbonyl)benzoic acid methyl ester
  参考文献：
  名称：

  发现苯甲酰胺类似物是一类新型的5-HT3受体激动剂

  摘要：

  在一个小型商业化合物库中筛选了一种基于苯甲酰胺支架的5‐HT 3受体激动剂，并进行了详细的SAR研究。苯甲酰胺类似物在5-HT 3 A受体处的设计，合成和功能表征，提供了有关该类似物作为5-HT 3受体激动剂的大量信息。但是，衍生的类似物的效力没有比最初的命中明显改善。苯甲酰胺支架构成了一种新型5‐HT 3受体激动剂，因为它不具有带正电的功能，这对于所有正构配体与受体的结合都是必不可少的。初步研究表明，这些化合物可通过与受体复合物中的变构位点结合来发挥其对5-HT 3受体的作用。

  DOI：

  10.1002/cmdc.201000444

文献信息

• A New Synthetic Method for the Preparation of Ketones by Denitration of α-Nitro Ketones
  作者：Noboru Ono、Masayuki Fujii、Aritsune Kaji

  DOI：10.1055/s-1987-27995

  日期：——

  The sequence of acylation of nitroalkanes and subsequent denitration of the resulting α-nitro ketones provides a new and general method for the preparation of ketones.

  硝基烷烃的酰化反应及其随后生成的一硝基酮的脱硝反应，提供了一种新的、普遍适用的酮制备方法。
• Combined Photoredox and Carbene Catalysis for the Synthesis of Ketones from Carboxylic Acids**
  作者：Anna V. Bay、Keegan P. Fitzpatrick、Rick C. Betori、Karl A. Scheidt

  DOI：10.1002/anie.202001824

  日期：2020.6.2

  development of a novel single-electron reduction of acyl azoliums for the formation of ketones from carboxylic acids. Facile construction of the acyl azolium in situ followed by a radical-radical coupling was made possible merging N-heterocyclic carbene (NHC) and photoredox catalysis. The utility of this protocol in synthesis was showcased in the late-stage functionalization of a variety of pharmaceutical compounds

  作为构建复杂有机支架的关键要素，CC键的形成仍然是合成有机化学领域的一个挑战。单电子化学的最新进展使得形成各种CC键的新方法成为可能。本文公开了用于由羧酸形成酮的酰基唑鎓的新型单电子还原的开发。通过合并 N-杂环卡宾 (NHC) 和光氧化还原催化，可以轻松地原位构建酰基唑鎓，然后进行自由基-自由基偶联。该方案在合成中的实用性在多种药物化合物的后期功能化中得到了展示。使用手性 NHC 的初步研究表明可以实现对映选择性，展示了该方案相对于替代方法的优势。
• Iminoacylation of Alkenes via Photoredox N-Heterocyclic Carbene Catalysis
  作者：Yi-Xiong Dong、Chun-Lin Zhang、Zhong-Hua Gao、Song Ye

  DOI：10.1021/acs.orglett.3c00006

  日期：2023.2.10

  alkene-tethered α-imino-oxy acids and acyl imidazoles. The corresponding substituted 3,4-dihydro-2H-pyrroles were afforded in moderate to good yields with good to high diastereoselectivities in most cases. The reaction involves the 5-exo-trig radical cyclization of an alkene-tethered iminyl radical and the following coupling with a ketyl radical from acyl imidazole under NHC catalysis.

  通过使用烯烃束缚的 α-亚氨基-氧酸和酰基咪唑，开发了通过光氧化还原 N-杂环卡宾催化的烯烃亚氨基酰化。在大多数情况下，相应的取代 3,4-二氢-2 H-吡咯以中等到良好的产率和良好到高的非对映选择性提供。该反应涉及烯烃束缚的亚胺基自由基的 5- exo -trig 自由基环化，以及随后在 NHC 催化下与来自酰基咪唑的羰基自由基偶联。
• ROR gamma (RORγ) modulators
  申请人：LEAD PHARMA HOLDING B.V.

  公开号：US10556866B2

  公开（公告）日：2020-02-11

  Novel compounds according to Formula I or a pharmaceutically acceptable salt thereof wherein: A11-A14 are N or CR11, CR12, CR13, CR14, respectively, with the proviso that no more than two of the four positions A can be simultaneously N; R1 is C(2-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1-3)alkyl)amino; R5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, (3-6)cycloalkylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl; the sulfonyl group with R1 is represented by one of R7, R8 or R9; R15 is H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl; and R16 is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl. The compounds can be used as inhibitors of RORγ and are useful for the treatment of RORγ mediated diseases.

  符合式 I 的新型化合物 或其药学上可接受的盐 其中A11-A14分别为N或CR11、CR12、CR13、CR14，但四个位置A中不能有两个以上同时为N；R1为C(2-6)烷基、C(3-6)环烷基、C(3-6)环烷基C(1-3)烷基、(二)C(3-6)环烷基氨基或(二)(C(3-6)环烷基C(1-3)烷基)氨基；R5 是 H、羟乙基、甲氧基乙基、C(1-6)烷基、C(6-10)芳基、C(6-10)芳基-C(1-3)烷基、C(1-9)杂芳基、C(1-9)杂芳基-C(1-3)烷基、C(3-6)环烷基、(3-6)环烷基-C(1-3)烷基、C(2-5)杂环烷基或 C(2-5)杂环烷基-C(1-3)烷基；R15 是 H、C(1-6)烷基、C(3-6)环烷基、C(3-6)环烷基-C(1-3)烷基、C(6-10)芳基、C(6-10)芳基-C(1-3)烷基、C(1-9)杂芳基、C(1-9)杂芳基-C(1-3)烷基、C(2-5)杂环烷基或 C(2-5)杂环烷基-C(1-3)烷基；R16 是 C(1-6)烷基、C(3-6)环烷基、C(3-6)环烷基 C(1-3)烷基、C(6-10)芳基、C(6-10)芳基 C(1-3)烷基、C(1-9)杂芳基、C(1-9)杂芳基 C(1-3)烷基、C(2-5)杂环烷基或 C(2-5)杂环烷基 C(1-3)烷基。这些化合物可用作 RORγ 的抑制剂，并可用于治疗 RORγ 介导的疾病。
• Synthesis of Dithiolethiones and Identification of Potential Neuroprotective Agents via Activation of Nrf2-Driven Antioxidant Enzymes
  作者：Zi-Long Song、Feifei Bai、Baoxin Zhang、Jianguo Fang

  DOI：10.1021/acs.jafc.9b06360

  日期：2020.2.19

  Oxidative stress is implicated in the pathogenesis of a wide variety of neurodegenerative disorders, and accordingly, dietary supplement of exogenous antioxidants or/and upregulation of the endogenous antioxidant defense system are promising for therapeutic intervention or chemoprevention of neurodegenerative diseases. Nrf2, a master regulator of the cellular antioxidant machinery, cardinally participates in the transcription of cytoprotective genes against oxidative/electrophilic stresses. Herein, we report the synthesis of 59 structurally diverse dithiolethiones and evaluation of their neuroprotection against 6-hydroxydopamine- or H2O2 -induced oxidative damages in PC12 cells, a neuron-like rat pheochromocytoma cell line. Initial screening identified compounds 10 and 11 having low cytotoxicity but conferring remarkable protection on PC12 cells from oxidative-mediated damages. Further studies demonstrated that both compounds upregulated a battery of antioxidant genes as well as corresponding genes' products. Significantly, silence of Nrf2 expression abolishes cytoprotection of 10 and 11, indicating targeting Nrf2 activation is pivotal for their cellular functions. Taken together, the two lead compounds discovered here with potent neuroprotective functions against oxidative stress via Nrf2 activation merit further development as therapeutic or chemopreventive candidates for neurodegenerative disorders.